Our history
-
2021Proof of Concept
Development of first functional prototype using mechanical joint damping. The technology proves effective in early user tests
-
2022Clinical Study
Together with the Reinier de Graaf hospital in Delft, we clinically proved the device to be effective for essential tremor
-
2023Medical Certification
Stil attains an ISO 13485 certification, obtaining recognition for its capacity to design, develop, and produce orthoses in conformity to medical regulations. The Stil Hand Control is given the CE mark.
-
2023Product launched (2023)
The launch of the product in the Netherlands.
-
2024International expansion
After the Netherlands, the product was launched in Germany (2024), Italy (2025), Belgium (2025) and the UK (2026).
-
FutureStandard treatment for tremor
Continuous research and development to make our products become the standard treatment for tremor
IJsbrand de Lange
IJsbrand is an entrepreneurial leader who founded STIL in 2017 after studying biomechanical engineering at TU Delft. Since then, he has guided the company through major challenges and key milestones, while keeping development closely aligned with user needs and growth objectives.
As CEO, he leads strategy, fundraising, clinical operations, and commercial scaling, having raised over €6 million, designed clinical studies, and built distributor partnerships. His mission is to make Stil a global player in movement disorder treatment.
Nicola Pambakian
Nicola joined Stil as CTO in 2019 after more than 10 years in R&D. He built strong expertise in medical technology through product development and leadership roles, including as Lead Engineer at a startup developing an automatic prosthetic knee.
At Stil, he brings a structured, detail-oriented, and user-centered approach to innovation. He leads the company’s certification efforts, including CE, FDA, and ISO 13485, manages its patent strategy, and oversees R&D development, driven by a strong belief in Stil’s mission.
Linze Dijkstra
Linze Dijkstra is an experienced Dutch healthcare investor and finance professional, currently serving as Investment Director at PGGM and Partner at Health Innovations.
With a background that includes leadership roles in healthcare finance at ABN AMRO, he has been active in health-tech investing since the late 2000s. Linze brings vital understanding on financial management and scaling up of healthcare start-ups.
Bart van Liebergen
Bart van Liebergen began his career in private equity before becoming CEO of Livit Orthopedie, the largest orthopedic and prosthetic service provider in the Netherlands.
There, he worked closely with manufacturers and led the company through a successful sale to private equity. At Stöpler Medical, he repeated this trajectory of scaling the business and managing its acquisition. Bart brings a strong track record in commercial strategy, and value creation leading up to exits.
Cees Zuiderwijk
Cees Zuiderwijk has over 40 years of experience in selling medical technology to distributors. At Enraf-Nonius, he led the global expansion in rehabilitation equipment.
At Bioness, he was responsible for introducing neuromodulation products like the H200 (arm orthosis) in the US and EMEA. He brings deep knowledge of go-to-market strategies, reimbursement of orthotics, distributor networks, and scaling medtech solutions internationally.
